Zeo ScientifiX, Inc. (ZEOX) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US68621D2062

Price
0.80 USD
Market cap
6.24 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Zeo ScientifiX, Inc. financials

Fiscal year2025
Revenue5.20 m USD
Gross profit4.27 m USD
Operating income-5.39 m USD
EBIT-5.42 m USD
Net income-5.52 m USD
Diluted EPS – continuing operations-0.86 USD

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Zeo ScientifiX, Inc.

Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarthritis,and traumatic brain injury. The company also provides Patient Pure X, an autologous biologic, that helps reduce inflammation and promote tissue healing and regeneration. In addition, it develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROWX, ZEO HAIR GROW, and ZEO GROW BOOST, a serum comprised of hair growth stimulants for follicle stimulation. The company has a strategic collaboration with Regen Therapy Limited for the development of biologic therapeutics. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is based in Davie, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.